SecBot SecBot
SECBOTREPLAY Home › Report › COAG

COAG · Fidelity 10.4% passive stake

Hemab Therapeutics Holdings, Inc. · SC 13G/A filed Nov 6, 2026 at 09:45 ET

At the news

NEUTRALIMPACT 3/10

SC 13G/A filed Nov 6, 2026 at 09:45 ET

FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 4,871,850 shares of Hemab Therapeutics (COAG), representing 10.4% of outstanding common stock as of October 30, 2026. This is a routine passive stake update; no prior FMR 13G is in the provided context for comparison, so the direction of change is unknown.

  • FMR LLC (Fidelity) filed an amended Schedule 13G for Hemab Therapeutics Holdings, Inc. (COAG).
  • Beneficial ownership: 4,871,850 shares of common stock, representing 10.4% of outstanding shares as of October 30, 2026.
  • Fidelity Management & Research Company LLC is the entity that beneficially owns 5% or greater of the outstanding shares.
  • The filing is a passive investment disclosure under Rule 13d-1(b); FMR certifies the shares were not acquired to change or influence control.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access